Neuronal gene expression is decreased in prefrontal cortex in schizophrenia

Vawter, Marquis P.; Weickert, Cynthia Shannon; Ferran, Erick; Matsuymoto, M.; Hyde, Thomas M.; Freed, W. J.; Kleinman, Joel E.; Weinberger, D.R.; Bunney, W. E.

doi:10.1016/s0920-9964(03)80585-6

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One clear observation from the published mRNA profiling studies [44,52,61], is that the quantitative changes associated with psychiatric disease are very small. Hardly any change crosses the twofold threshold that is considered by many investigators to be at the low end of what can be considered significant.…”

Section: Discussionmentioning

confidence: 99%

Proteomics in the Discovery of New Therapeutic Targets for Psychiatric Disease

Voshol

Glucksman²,

Oostrum³

2003

CMM

View full text Add to dashboard Cite

In terms of impact on and cost to society psychiatric disorders are among the most important health problems of today. Current estimates from the US suggest that the collective cost of psychiatric diseases could amount to one-third of the total health care budget with a cumulative lifetime prevalence of 30%. While undoubtedly improvements have been made in the diagnosis and treatment of at least the symptoms of mental illness, there has been frustratingly little progress in elucidating the molecular mechanisms. However, a fundamentally different approach to study molecular mechanisms of psychiatric diseases is emerging as a result of technological advances in expression profiling methods. This comprises the investigation of the expressed disease 'phenotypes', developing from the differential gene and protein expression in the central nervous system as a result of the complex interaction between genetic predisposition and environmental modulation. This paper will focus on proteomics, expression profiling at the protein level, reviewing some of the available tools and their application in the molecular analysis of psychiatric disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Proteomics in the Discovery of New Therapeutic Targets for Psychiatric Disease

Voshol

Glucksman²,

Oostrum³

2003

CMM

View full text Add to dashboard Cite

show abstract

“…Whilst neurodegenerative disease with marked changes in brain structure perhaps provide ready uses for high throughput microarray analysis, neuropsychiatric disease with more subtle changes in neurochemistry provide a particular challenge to the abilities of microarray analysis. Using these high throughput approaches, however, has shown consistent patterns of gene expression changes in disorders such as schizophrenia, where disregulation of genes involved in synaptic function and metabolism are seen in prefrontal cortex in post‐mortem brain samples from affected individuals (Lewis et al, 2003; Middleton et al, 2002; Mirnics et al, 2000; Tkachev et al, 2003; Vawter et al, 2004; Hashimoto et al, 2003) and in oligodendrocyte function (Hakak et al, 2001; Tkachev et al, 2003).…”

Section: Genomicsmentioning

confidence: 99%

High throughput approaches in neuroscience

Morris

Wilson

2004

Intl J of Devlp Neuroscience

View full text Add to dashboard Cite

Traditional approaches to understanding biological problems are now being advanced with the use of high throughput technologies, which analyse multiple samples simultaneously, or thousands of analytes in a single sample. The application of these technologies in neurochemistry and neuroscience is beginning to be explored and is assisting in the development of new models of drug action, neuroanatomical investigations, and in identifying molecular pathways involved in neurological and psychiatric disease. Tools such as microarray-based gene expression profiling and 2D and multidimensional proteomic methods are uncovering functional components to a wide variety of neuroscience paradigms and the application of these technologies is set to become standard in analysis.

show abstract

“…Μάλιστα, φαίνεται να υπάρχει η τάση η μείωση αυτή να είναι πιο έντονη στα πιο προχωρημένα στάδια της νόσου. [Middleton et al, 2002;Vawter et al, 2003;Hakak et al, 2001], καθώς επίσης και κατά την αγωγή αντιψυχωτικών φαρμάκων [Middleton et al, 2002]. [Dracheva at al., 2001;Grimwood et al, 1999;Mueller et al, 2004], όσο και του υποδοχέα της σεροτονίνης 1α στο προμετωπιαίο φλοιό και στο temporal cortex [Hashimoto et al, 1991, Simpson et al, 1996 έχουν παρατηρηθεί σε σχιζοφρενείς ασθενείς.…”

Section: α332 σχιζοφρένειαunclassified

Μελέτη γονιδίων που εμπλέκονται σε μηχανισμούς νευροεκφύλισης στο γενετικό μοντέλο ντοπαμινεργικής απονεύρωσης μυός weaver και σε λεμφοκύτταρα παρκινσονικών ασθενών

Spathis¹,

Σπάθης²

View full text Add to dashboard Cite

show abstract

Neuronal gene expression is decreased in prefrontal cortex in schizophrenia

Cited by 4 publications

References 0 publications

Proteomics in the Discovery of New Therapeutic Targets for Psychiatric Disease

Proteomics in the Discovery of New Therapeutic Targets for Psychiatric Disease

High throughput approaches in neuroscience

Contact Info

Product

Resources

About